Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease

Clinical Rheumatology

Volumn 33, Issue 11, 2014, Pages 1643-1648

  Tsuruta, Yuki ^a   Mochizuki, Toshio ^a   Moriyama, Takahito ^a   Itabashi, Mitsuyo ^a   Takei, Takashi ^a   Tsuchiya, Ken ^a   Nitta, Kosaku ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Allopurinol; Chronic kidney disease; eGFR; Febuxostat; Hyperuricemia; Uric acid

Indexed keywords

ALBUMIN; ALDOSTERONE; ALLOPURINOL; AMINOTRANSFERASE; ANGIOTENSIN; CREATININE; FEBUXOSTAT; HEMOGLOBIN; URIC ACID; ANTIGOUT AGENT; THIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CHEMICAL PARAMETERS; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG SUBSTITUTION; FEMALE; GLOMERULUS FILTRATION RATE; GOUT; HEMODIALYSIS; HUMAN; HYPERURICEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PURINE METABOLISM; SIDE EFFECT; URIC ACID BLOOD LEVEL; BLOOD; CHRONIC KIDNEY FAILURE; COMPLICATION; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALLOPURINOL; DISEASE PROGRESSION; DRUG SUBSTITUTION; FEMALE; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; KIDNEY; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; THIAZOLES; TREATMENT OUTCOME; URIC ACID;

EID: 84919330288     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-014-2745-5     Document Type: Article

References (27)

1. Cirillo P, Sato W, Reungjui S, Heinig M, Gersch M, Sautin Y, Nakagawa T, Johnson RJ (2006) Uric acid, the metabolic syndrome, and renal disease. J Am Soc Nephrol 17:S165–S168
2. Edwards NL (2008) The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med 75(Suppl 5):S13–S16
3. Miyaoka T, Mochizuki T, Takei T, Tsuchiya K, Nitta K (2013) Serum uric acid levels and long-term outcomes in chronic kidney disease. Heart Vessels [Epub ahead of print]
4. Nakagawa T, Kang DH, Feig D, Sanchez-Lozada LG, Srinivas TR, Sautin Y, Ejaz AA, Segal M, Johnson RJ (2006) Unearthing uric acid: an ancient factor with recently found significance in renal and cardiovascular disease. Kidney Int 69:1722–1725
5. Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R (2008) Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 19:2407–2413
6. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–1305
7. Feig DI, Kang DH, Johnson RJ (2008) Uric acid and cardiovascular risk. N Engl J Med 359:1811–1821
8. Liu WC, Hung CC, Chen SC, Yeh SM, Lin MY, Chiu YW, Kuo MC, Chang JM, Hwang SJ, Chen HC (2012) Association of hyperuricemia with renal outcomes, cardiovascular disease, and mortality. Clin J Am Soc Nephrol 7:541–548
9. Odden MC, Amadu AR, Smit E, Lo L, Peralta CA (2014) Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002. Am J Kidney Dis [Epub ahead of print]
10. Keenan RT, O’Brien WR, Lee KH, Crittenden DB, Fisher MC, Goldfarb DS, Krasnokutsky S, Oh C, Pillinger MH (2011) Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med 124:155–163
11. Nakaya I, Namikoshi T, Tsuruta Y, Nakata T, Shibagaki Y, Onish Y, Fukuhara S, School of Designing Clinical Study for Nephrologists and Dialysis Physicians (2011) Management of asymptomatic hyperuricaemia in patients with chronic kidney disease by Japanese nephrologists: a questionnaire survey. Nephrology (Carlton) 16:518–521
12. Thurston MM, Phillips BB, Bourg CA (2013) Safety and efficacy of allopurinol in chronic kidney disease. Ann Pharmacother 47:1507–1516
13. Japanese Society of Nephrology (2012) Evidence-based practice guideline for the treatment of CKD. Clin Exp Nephrol 13:537–566
14. Fang J, Alderman MH (2000) Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 283:2404–2410
15. Culleton BF, Larson MG, Kannel WB, Levy D (1999) Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 131:7–13
16. Madero M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, Collins AJ, Levey AS, Meno V (2009) Uric acid and long-term outcomes in CKD. Am J Kidney Dis 53:796–803
17. Borges RL, Hirota AH, Quinto BM, Ribeiro AB, Zanella MT, Batista MC (2009) Uric acid as a marker for renal dysfunction in hypertensive women on diuretic and nondiuretic therapy. J Clin Hypertens (Greenwich) 11:253–259
18. Bellomo G, Venanzi S, Verdura C, Saronio P, Esposito A, Timio M (2010) Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis 56:264–272
19. Hovind P, Rossing P, Tarnow L, Johnson RJ, Parving HH (2009) Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes 58:1668–1671
20. Hsu C, Iribarren C, McCulloch CE, Darbinian J, Go AS (2009) Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med 169:342–350
21. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhakar S, Johnson RJ (2005) Hyperuricemia induces endothelial dysfunction. Kidney Int 67:1739–1742
22. Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML (2008) Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 26:269–275
23. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A, Arroyo D, Luño J (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5:1388–1393
24. Siu YP, Leung KT, Tong MK, Kwan TH (2006) Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 47:51–59
25. Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, Lademacher C (2010) The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 12:R63
26. Sakai Y, Otsuka T, Ohno D, Murasawa T, Sato N, Tsuruoka S (2014) Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease. Ren Fail 36:225–231
27. Stamp LK, O’Donnell JL, Zhang M, James J, Frampton C, Barclay ML, Chapman PT (2011) Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 63:412–421